Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Remy_Luthringer
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developsDrug |
gptkb:roluperidone
gptkb:seltorexant |
| gptkbp:focusesOn |
neurological disorders
central nervous system disorders psychiatric disorders |
| gptkbp:foundedYear |
2007
|
| gptkbp:headquartersLocation |
gptkb:Waltham,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Minerva Neurosciences
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:publiclyTraded |
true
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:NERV
|
| gptkbp:website |
https://www.minervaneurosciences.com/
|
| gptkbp:bfsParent |
gptkb:William_J._Doyle
|
| gptkbp:bfsLayer |
6
|